Patents by Inventor John Schneekloth

John Schneekloth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210261516
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 26, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 11014902
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: May 25, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Publication number: 20200308128
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: March 30, 2020
    Publication date: October 1, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Patent number: 10604499
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 31, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Publication number: 20190100503
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 4, 2019
    Applicants: The United States of America as represented by the Secretary, Department of Health and Human Service, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 10196372
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: February 5, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Yale University
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Publication number: 20180030018
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: January 5, 2016
    Publication date: February 1, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Publication number: 20050245435
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 14, 2005
    Publication date: November 3, 2005
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, John Schneekloth, John Chabala